Long term survival in a patient with variant Creutzfeldt–Jakob disease treated with intraventricular pentosan polysulphate

AUTOR(ES)

Parry, A

FONTE

BMJ Group

RESUMO

Variant Creutzfeldt‐Jakob disease (vCJD) is a neurodegenerative disease that principally affects young people and has a median duration of illness of 13 (range 6–39) months. vCJD is incurable and there are currently no treatments that conclusively slow the rate of disease progression. However, recent animal studies and isolated case reports have suggested that treatment with intraventricular pentosan polysulphate (PPS) may be beneficial in the treatment of patients with vCJD.

Documentos Relacionados

• Diagnostic approach in a patient with Creutzfeldt-Jakob disease
• Short report: Creutzfeldt-Jakob disease treated with amantadine
• The Heidenhain variant of Creutzfeldt-Jakob disease
• Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease
• Increased serum neopterin concentrations in a patient with Creutzfeldt-Jakob disease.